3 Stocks I Saw on T...
Health Care: Drugs
Flamel Technologies (FLML: NASDAQ)
$4.43 0.09 | 1.98%
06/04/12 - 12:14 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | n.a. | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 0.64 | 0.94 | 0.98 |
| Price to Sales (TTM) | 3.32 | 4.21 | 1.42 |
| Price to Book (MRQ) | 3.64 | 3.38 | 2.41 |
| Price to Tangible Book (MRQ) | 3.64 | -8.72 | 5.08 |
| Price to Cash Flow (TTM) | -20.00 | 274.70 | 9.80 |
| Price to Free Cash Flow (TTM) | -8.90 | -63.90 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.00 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 1.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | 23.61 | -0.76 |
| Payout Ratio (TTM) | 0.00 | n.a. | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -35.70 | 37.70 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | -12.10 | 1.60 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 5.46 | 7.01 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | 225.80 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | -100.00 | 225.80 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -25.22 | 4.51 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.80 | 1.40 | 1.10 |
| Current Ratio (MRQ) | 2.00 | 2.40 | 1.60 |
| LT Debt to Equity (MRQ) | 0.07 | 0.90 | 0.82 |
| Total Debt to Equity (MRQ) | 0.14 | 0.91 | 0.96 |
| Interest Coverage (TTM) | n.a. | 0.70 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 91.00 | 54.60 | 46.90 |
| Gross Margin - 5 Yr Avg | 87.80 | 54.70 | 47.70 |
| EBITD Margin (TTM) | -19.00 | 17.90 | 18.90 |
| EBITD - 5 Yr Avg | -36.52 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -26.30 | -1.60 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | -46.40 | -1.20 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.27 | -0.01 | 0.09 |
| Net Profit Margin - 5 Yr Avg | -42.20 | -1.20 | 7.00 |
| Return on Assets (TTM) | -12.60 | -0.40 | 3.10 |
| Return on Assets - 5 Yr Avg | -18.30 | -0.60 | 2.50 |
| Return on Investment (TTM) | -27.00 | -0.60 | 7.90 |
| Return on Investment - 5 Yr Avg | -35.00 | -0.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 122,097.00 | 379,608.00 | 449,376.00 |
| Net Income/Employee (TTM) | -32,861.00 | -4,557.00 | 39,003.00 |
| Receivable Turnover (TTM) | 3.70 | 6.60 | 7.60 |
| Inventory Turnover (TTM) | 2.30 | 2.90 | 8.30 |
| Asset Turnover (TTM) | 0.50 | 0.50 | 0.40 |
Portfolios with FLML
- Portfolio NameUser Type
- Contributor10 Top-Rated Buys Under $10
- Contributor10 Stocks Under $10 With Up...
- Usergreentree
- UserSalvelinus Fontinalis
- UserBVF Inc.
- UserBoondoggler22 Portfolio 1
- UserFATZ 1
- Userndecas Portfolio 1
- UserRooster Fund
- UserLGS-1 Portfolio 1
Latest FLML Headlines from TheStreet
- Flamel Technologies' CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.07.12 | 11:05 am
- Flamel Technologies' CEO Discusses Q4 2011 Results - Earnings Call Transcript 03.15.12 | 01:03 pm
- Flamel Technologies's CEO Discusses Q3 2011 Results - Earnings Call Transcript 11.03.11 | 11:11 am
- Flamel Technologies CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.26.11 | 01:07 pm
- Flamel Technologies CEO Discusses Q1 2011 Results - Earnings Call Transcript 05.09.11 | 10:05 am
- Flamel Technologies CEO Discusses Q4 2010 Results - Earnings Call Transcript 03.04.11 | 12:03 pm
- Flamel Technologies CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 11:11 pm
- Flamel Technologies SA Q2 2010 Earnings Call Transcript 07.29.10 | 02:07 pm
- Thursday's Health Winners & Losers 12.20.07 | 02:12 pm
- Wednesday's Health Winners & Losers 12.05.07 | 04:12 am
Press Releases for FLML
- Flamel Technologies Announces First Quarter 2012 Results - Business Wire 05.07.12 | 07:05 am
- Flamel Technologies Announces Fourth Quarter And Year-End 2011 Results - Business Wire 03.14.12 | 06:03 pm
- Flamel Technologies Announces Acquisition Of Éclat Pharmaceuticals - Business Wire 03.14.12 | 06:03 pm
- Flamel Technologies Announces Profitable Third Quarter Results - Business Wire 11.02.11 | 04:11 pm
- Flamel Technologies Announces Multi-Year Supply Agreement With GlaxoSmithKline For Coreg CR™ Microparticles - Business Wire 10.18.11 | 08:10 am
- Eagle Pharmaceuticals And Flamel Technologies Announce Eagle To License Medusa Technology For Extended-Release Of Tigecycline - Business Wire 10.13.11 | 09:10 am
- Flamel Technologies And Digna Biotech Announce Multiple Product Development Agreement - Business Wire 06.27.11 | 08:06 am
- Flamel Technologies Announces Results Of Annual Meeting - Business Wire 06.24.11 | 08:06 am
- Flamel Technologies Announces Nomination Of Ambassador Craig Stapleton, Dr. Catherine Bréchignac And Mr. Guillaume Cerutti For Election To The Board Of Directors - Business Wire 05.31.11 | 08:05 am
- Flamel Technologies Announces Expanded Partnership Relations; First Quarter Results - Business Wire 05.09.11 | 06:05 am
Partner Headlines for FLML
- 16 Micro-Cap Stocks Being Targeted By Short Sellers - Seeking Alpha 10.26.11 | 09:10 am
- Investors roll positions on options expiration day - Reuters 08.20.10 | 03:08 pm
- Zacks #5 Rank Additions for Wednesday - Tale of the Tape - Zacks 08.04.10 | 09:08 am
